Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > THE SKY IS THE LIMIT ? ARE YOU RETARDED POLO?

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 31, 2022 5:14pm

176 Views

Post# 34564705

RE:THE SKY IS THE LIMIT ? ARE YOU RETARDED POLO?

Hello, my name is Bob Farrell and I'm a paid pumper. LOLOLOLOL

I try to avoid insults and never do so first, but how dumb can you be.

Plus I have offered all you who accuse me of being a pumper opportunity to have an actual face to face conversation over Zoom and you all refuse, Why? You think because you lie, insult and hide behind your fake profile everyone else doe as well.

<< Previous

Bullboard Posts

Next >>

Meet Canopy USA’s new CEO, Brooks Jorgensen